An Artificial Intelligence tool that could change the way we treat heart disease wowed the judges at this year’s Bright SCIdea competition. Now that the dust has settled, we asked Raphael Peralta, from the winning CardiaTec team, about winning the competition, the need for this technology, and tips for future participants. After winning this prestigious competition and coming away with the £5,000 first prize, the future is bright for co-founders Raphael Peralta, Thelma Zablocki and Namshik Han. So, how do they reflect on the story so far?
Team CardiaTec (UK)
Tell us about CardiaTec
Cardiovascular disease is the world’s leading cause of death, and affects countless lives. Despite this, investment and innovation within the space has been severely stagnated, especially in comparison to fields such as oncology. The current treatment landscape remains unchanged, and treatments are most often prescribed in a standardised, one-size-fits-all approach. However, people are fundamentally different, and as shown by the Covid-19 pandemic, similar groups of people can experience a disease in a significantly different manner, and as such it is very important to understand biological processes at a patient level to produce effective therapeutic outcomes.
CardiaTec is leveraging artificial intelligence to structure and analyze large scale biological data that spans the full multiomic domain. This allows for a comprehensive understanding of disease pathophysiology to better develop novel and effective therapeutics for cardiovascular disease.
Casting your mind back to the moment you were announced the winner of Bright SCIdea 2020, what were your initial thoughts?
We thought we had a good opportunity to win it, but obviously when it was announced, it was a great feeling. Winning this competition is a further validation that what we are generating has real world value.
It was a great judging panel, with a breadth of experience across drug discovery and the pharmaceutical industry. We were up against immense global competition and the fact that we won shows that there’s a need for novel innovation in the cardiovascular space to ultimately drive the development of new therapeutics that are going to help change people's lives.
How did you think of the idea? Was there a ‘eureka’ moment?
The way the initial idea came about was through the identification that the cardiovascular space had a massive unmet need compared to other spaces such as oncology. I had worked with a cardiovascular company doing some consulting work and this is where it came to light.
In combination, multiomic techniques are becoming increasingly accessible in line with technological developments, which have made processes of next generation sequencing and proteomic profiling increasingly cheaper. These processes generate large amounts of data, which then lend themselves to applications of machine learning to derive biologically meaningful insights. These process, although becoming increasingly familiar in areas such as oncology, are highly underrepresented in cardiovascular disease, and thus there spans opportunity to develop completely unique and novel insights.
How does the technology work?
Here, CardiaTec uses data across genomics, epigenomics, transcriptomics, proteomics, and metabolomics, to generate novel biological insights with the help of AI and machine learning applications. Taking these many ‘omics’ into consideration is what defines a ‘multiomic’ approach. Biology is complex, and trends require full multiomic assessment to truly understand where dysregulation of specific processes is occurring, to then inform the best means of intervention.
CardiaTec is developing a platform, which with time will grow to become one of the most comprehensive foundations of cardiovascular disease biology. Results and outcomes are iteratively incorporated into the model, and new hypotheses are tried and tested across a range of pre-clinical settings. Collectively, CardiaTec aims to generate novel drug targets that can be used to help reduce the burden of disease in current and future patient population.
In the process of getting to the final, there were several opportunities to engage with entrepreneurs, investors, business leaders, and experts in intellectual property (IP). Can you share key takeaways from these sessions?
One of the most important things you can do is speak to people. Every business starts from an idea. As you start developing, you change and refine the business model. We take every chance to engage with people who have industry experience. It’s really important that we take the advice of these people on board; this is especially true in the field of biotechnology where you take risks across the technology side, the commercial side, and the biological side. It takes a lot of experience to mitigate those risks.
How difficult has it been taking that idea and turning it into a viable business proposition?
Thelma and I came out of the MPhil in Bioscience Enterprise at the University of Cambridge. It gave us this really strong foundation to start building. We also had the biological knowledge from our previous degrees. This framework, where we had key opinion leaders and great people in the field with whom we could bounce ideas off, was the first step. We saw that the idea was really positive and was received well by a lot of people. So, we thought: ‘we’re onto something’.
When building a biotech company, if you’re not passionate about it and don’t want to spend a lot of your time dedicated to the project, then it’s not going to take off. You need to be there to make changes, and really embrace and understand where you believe it’s going to go in line with the advice you've been given and the insights that you have generated.
We’re not only interested in understanding the intricate nature of biology. We’re also interested in how this has real life application in changing people’s lives. Every person we speak to has been affected in some way by cardiovascular disease.
I noticed that your presentation was really polished. Do you have any tips for people presenting in the final?
We’ve presented a lot of times so I think practice makes perfect. With a presentation, you need to be able to tell a story. It’s all about the storyline and building that image. You have to take care and be diligent in the process. Take time to make sure everything is structured correctly and that the story flows. Don’t be afraid to present to a lot of people who will give you advice. Take the time to make the amendments and run it through again and again, and see what the response is. So, take your time on the presentation to get your story across.
You were both very calm when the judges’ questions came. How did you prepare for these questions?
Out of this Cambridge network, the people we spoke to all asked the right questions. You see the pattern of these questions. They all want to know similar things. So, once we identified that pattern, we wrote down the questions that were important from our conversations and we practiced responses to these questions, which were by this point, fully embedded into the company’s business model; which then lends itself to an insightful, actionable response.
How are you going to use the £5,000 prize money and what’s next?
We’ll put the prize money towards refining of some of our technology. In terms of what’s next, Thelma (Zablocki), Namshik (Han), and I are dedicated to this company. We want to see it through and eventually make a drug that ends up reaching patients. This will take a long time.
To see that in the real world, where someone’s getting prescribed a drug that you discovered would be incredible.
>> For more on this year’s Bright SCIdea final, go to: https://www.soci.org/news/2022/3/bright-scidea-final-2022.
How do you create an investor-ready intellectual property (IP) approach to help you secure that all-important funding? We asked Charlotte Crowhurst, patent attorney at leading European IP firm, Potter Clarkson.
As businesses focus on growth in the post-pandemic world, innovation is vital. Being able to turn good ideas into a commercial success – at scale – can have a transformational impact on the wider economy. Scientists and engineers have been front and centre in providing solutions to the health crisis, but they will also play an essential role in the economic recovery.
Of course, even the most ground-breaking invention requires investment to become a viable market proposition. Yet, the road to securing funding is not always straightforward or clear, with various hurdles to overcome before winning the trust and backing of investors. Securing funding is fiercely competitive territory, as investors apply a forensic approach to identifying the risks and opportunities with each investment target.
Intellectual property alone will not likely secure funding, but a weak IP position could significantly impact on valuation – by as much as 70% – or even see an investor walk away altogether. What’s more, for return-hungry investors, new research shows that SMEs with intellectual property rights generate 68% higher revenues per employee than those who don’t.
For ambitious, high growth SMEs to put themselves in the strongest position to attract and secure funding, there are five key ingredients that make up an investor-ready IP approach:
This is the number one deal breaker. Make sure there are no grey areas on ownership of IP. Any grey areas surrounding who ‘owns’ IP will signal alarm bells for a potential investor.
Understanding what IP your business may have and what you might be able to protect is not always obvious. It is always worth seeking professional advice early on to determine which IP rights you might be able to secure.
Robust processes and procedures are also important. Create an IP register and keep it up to date monthly so that opportunities are not overlooked. Do not underestimate the importance of robust processes and procedures.
Understanding what IP you need to protect isn’t always obvious.
Put yourself in an investor’s shoes – they are focused on whether you can provide a return on their investment. They are looking for clarity in your approach – a strategically sound business plan, where it is easy to see how the IP rights will help to achieve the commercial objectives.
>> Need more information on filing a chemistry patent. Read our blog on chemistry patent filing.
A growing business can be all-consuming, but a sound IP approach takes into consideration the wider marketplace in which your business is operating and any potential third-party rights.
Knowing when to act is critical to a sound IP approach. Knowing which steps to take and when to take them can have a critical impact on the strength of your IP position.
The end goal
Ultimately, the end goal with IP due diligence is to instil confidence and build trust with a potential investor. While investors are prepared to take on varying degrees of risk, SMEs will always need to show an IP approach that doesn’t signal alarm bells.
Put simply, those SMEs who are clear on these five areas will reduce the chances of IP being the reason an investor walks away.
>> To read more on ensuring your IP is investor-ready, visit the Potter Clarkson website here.
Edited by Eoin Redahan. You can find more of his work here.
Are you thinking of filing a chemical industry patent in 2022? Anthony Ball, Senior Associate at patent attorney Abel + Imray, gave us the lowdown about what you need to know about the process, cost, and filing your patents in different countries.
I’ve developed a novel technology. How do I patent it, how long does it take, and how much could it cost?
The first step in patenting a novel technology is to file a patent application. The patent application must contain a description of the technology that you have developed in enough detail for others to work the invention. It also needs to contain some claims that define the protection you think you are entitled to. Before the application is filed, it is also important to sort out who the inventors are and who owns the invention.
The application is then examined, during which the Patent Office and you come to an agreement regarding the extent of protection that you are entitled to. Once the extent of protection is agreed, the patent will proceed to grant.
The application will be published around 18 months from filing. This allows competitors to see what you intend to protect. It usually takes longer for the patent to be granted (and so be enforceable) - usually from four to 10 years. For a UK patent which protects a chemical invention, the total cost might be around £10,000.
A separate patent is required for each country that you are likely to want to stop competitors using your technology. Obtaining patents in the most important markets might cost in excess of £50,000 for a chemical invention. Although this might sound like a lot of money, not all of this needs to be paid at the start of the process. Instead, it is spread out over a few years, with the biggest investment usually coming three years into the process.
You mentioned that you can obtain a patent for a compound, a formulation, or a process for synthesising compounds. Does the patent process and cost vary according to the type of product or the branch of chemistry?
The overall process – filing a patent application, the patent application being examined and then the patent being granted – is the same for all technologies. However, there are some issues faced in certain branches of chemistry (such as pharmaceuticals) which can be quite difficult to overcome, and are not faced as commonly in other branches of chemistry. Because of this, it can sometimes take longer for patents in these fields to be granted than in other fields of chemistry, and the costs can be higher.
In which scientific areas has there been a recent rise in patent applications and are any fields relatively under-represented by comparison?
Focusing on European Patent Applications, the chemical industry has been fairly strong recently. Pharmaceutical and biotechnology in particular saw relatively large increases in the number of European patent applications filed in 2020, although the number of patents in the organic fine chemical field slightly decreased.
I want to file my patent in several countries. What do I do, and how much do the costs vary, depending on the country? For example, how would the cost of a patent in the UK compare to one in the US?
If you wish to have a patent in several countries, the start of the process is the same as the one described earlier; a patent application is filed in one country. Then, the most cost effective way to extend the protection to other countries is usually to file a “PCT application” within a year of filing the original application. After a further 18 months, you can turn this PCT application into applications for most countries around the world, including Europe, the US, China and India.
Costs do vary between different countries. To use the example above, it might cost 50-100% more to obtain a patent in the US than in the UK alone. It is worth noting that a patent for the same technology from the European Patent Office might cost around the same as a patent in the US, but the patent from the European Patent Office can then be converted into a patent in each country in the EU, plus some others (including the UK, Norway and Switzerland). Unfortunately, it is difficult to be precise about costs, because they depend very much on the number and type of objections raised by the patent office examiners.
One other consideration is translations. For long applications (which can be quite common in some branches of chemistry), these can be expensive, adding thousands of pounds to the cost for obtaining a patent. One country in particular where a translation might be required, and is of growing importance in the chemical area, is China.
Patents from the European Patent Office are valid across the EU and in several other countries. | Editorial credit: nitpicker / Shutterstock.com
>> From patents to green chemistry and agrifood, we have some great events coming up. Find out more on our event page.
Is there anything chemists and chemistry industry professionals should be particularly mindful of when submitting patent applications in 2022?
Patent law is underpinned by a number of international agreements, which are hard to renegotiate. As a result, the law is actually very stable over time, and so the considerations in 2022 will broadly be the same as they have been in the past. Having said that, one important thing to bear in mind at the moment is the amount of data to include in the patent application.
There is a balance between filing as soon as possible (to prevent a competitor getting there first, and to minimise the chance of a disclosure of something that would make your technology unpatentable), and making sure that the application has enough data to show that the extent of protection that you are asking for is justified. In some cases, it is possible to present data to justify the scope of protection after the application has been filed, but recently many patent offices have made that more and more difficult.
As such, filing too early, and with only a small amount of data to support your claims, could result in a very narrow patent, which might potentially be easy to work around. It is very important to include enough evidence to show that at least the parts of your invention which have the most commercial interest (e.g. the most active compounds) show the technical effect which is mentioned in the patent application.
How much have the law and process around patents changed in recent years?
The law around patents and patent applications is always evolving, albeit slowly. The basics – that the technology must be new, not be obvious in view of publicly available knowledge, and have an industrial application – have remained the same for many years. Likewise, the basic process to obtain a patent, as described above, has not changed recently, but the minor details of that process are constantly being updated, for example to incorporate new technology (such as online filing of the application and supporting documents, and online publication of the application) and to improve cooperation between the patent systems of different countries.
An example of improved cooperation between countries is the Unified Patent Court (UPC), which is likely to begin hearing cases in 2022. Currently, patents have to be enforced in each EU country separately using the national court systems. The UPC will establish a common court system and allow a patent to be enforced in one court case, with the result being valid for the whole of the EU.
I have made a further development to my technology after filing my patent application. How can I protect my new development?
Once it has been filed, nothing can be added to a patent application. Because of this, if you want to protect a new development to the technology that is the subject of a patent application, then another patent application must be filed directed to the new development. The two applications will be treated separately, and so in order for a patent to be granted which protects the new development, the new development must satisfy all the criteria for patentability described above.
To read more from Abel + Imray on patents, visit: https://www.abelimray.com/
At COP26, Nikita Patel co-hosted the Next-Gen debate, where an inspiring group of young people discussed how chemistry is tackling climate change. The PhD student at Queen Mary University of London shares her experience.
While the United Nations Climate Change Conference (COP26) may be over, there is still plenty to be done in the fight against climate change. We’ve seen what can be achieved when we work together and no doubt science will play a key role.
On Thursday 4 November, I had the privilege of co-hosting the Countdown to Planet Zero Next-Gen debate organised by SCI to showcase the work being carried out by our young and innovative scientists to tackle climate change. It was a real pleasure to share the stage and hear from some great scientists, exploring the themes Fuels of the Future, Turning Waste into Gold and Engineering Nature. The event gave the audience the opportunity to question and challenge the panel members on their climate change solutions.
Panel L-R: Dominic Smith, Natasha Boulding, Clare Rodseth, Jake Coole, Nikita Patel, Oliver Ring (Brett Parkinson joined virtually).
While I was feeling nervous about my hosting duties, I was very excited at the same time as I knew how important it was to educate the audience, whether they were members of the public or aspiring scientists, on how science is crucial in battling the climate emergency.
An important part of my role as a host was to ensure the incoming questions and comments were understood by all, given the mixed audience attending. This highlighted how essential good science communication is to prevent misunderstandings and the spread of misinformation.
It was brilliant to see how engaged the audience were from the flurry of questions that came in during the session, so much so that we didn’t manage to get through all of them! There were a wide variety of questions aimed at particular panellists but also towards the panel as a whole. It was thought-provoking to hear how scientists from different backgrounds offered their own perspectives on the same topic.
4 November was also Energy Day at COP26 and the atmosphere was buzzing! I learnt a lot from attending the Green Zone, not only from our panellists but from all the exhibitors present too. I appreciate the small, individual actions we can each take that will make a difference but also the need to work together to achieve the common goal of fighting climate change. It was clear to see how science and business go hand in hand to provide solutions to society and how interdisciplinary collaboration is key.
The result of our poll question: ‘Do you think that science is pivotal in providing climate change solutions?’ spoke for itself, with a resounding yes from 100% of the audience participants! This was a very positive outcome and showed that it is not all doom and gloom when it comes to discussing the climate crisis.
On a personal level, I'm going to continue implementing some simple changes like using public transport more, eating more vegan food and flying less and aim to keep the discussion going with my peers as the climate emergency is far from over.
SCI team, panellists and hosts.
I hope the youth panel event has inspired the next generation of scientists and showcased some of the exciting work that is going on behind the scenes which people may not realise and ultimately, that there is hope in science.
>> To rewatch the event, the recording is available on the COP26 YouTube channel: Countdown to Planet Zero Combating climate change with chemistry | #COP26, and on our Climate Change Solutions hub.
>> Want to read more about the technologies discussed by our panel? Read our event review: https://www.soci.org/blog/2021/11/2021-11-05-cop26-review.
We are increasingly conscious of the need to recycle waste products, but it is never quite so easy as rinsing and sorting your waste into the appropriate bins, especially when it comes to plastic.
Despite our best intentions, only around 16% of plastic is recycled into new products — and, worse, plastics tend to be recycled into low quality materials because transformation into high-value chemicals requires substantial amounts of energy, meaning the choices are either downcycling or prohibitively difficult. The majority of single-use plastics end up in landfills or abandoned in the environment.
This is a particular problem when it comes to polyolefins such as polyethylene (PE) and polypropylene (PP), which use cheap and readily available raw materials. Approximately 380 million tonnes of plastics are generated annually around the world and it is estimated that, by 2050, that figure will be 1.1 billion tonnes. Currently, 57% of this total are polyolefins.
Why are polyolefins an issue? The strong sp3 carbon–carbon bonds (essentially long, straight chains of carbon and hydrogen atoms) that make them useful as a material also make them particularly difficult to degrade and reuse without intensive, high energy procedures or strong chemicals. More than most plastics, downcycling or landfill disposal tend to be the main end-of-life options for polyolefins.
Polyethylene is used to make plastic bags and packaging.
Now, however, a team of scientists from MIT, led by Yuriy Román-Leshkov, believe they may have made a significant step towards solving this problem.
Previous research has demonstrated that noble metals, such as zirconium, platinum, and ruthenium can help split apart short, simple hydrocarbon chains as well as more complicated, but plant-based lignin molecules, in processes with much lower temperatures and energy.
So the team looked at using the same approach for the long hydrocarbon chains in polyolefins, aiming to disintegrate the plastics into usable chemicals and natural gas. It worked.
First, they used ruthenium-carbon nanoparticles to convert more than 90% of the hydrocarbons into shorter compounds at 200 Celsius (previously, temperatures of 430–760 Celsius were required).
Next, they tested their new method on commercially available, more complex polyolefins without pre-treatment (an energy intensive requirement). Not only were the samples completely broken down into gaseous and liquid products, the end product could be selected by tuning the reaction, yielding either natural gas or a combination of natural gas and liquid alkanes (both highly desirable) as preferred.
Polypropylene is used in bottle caps, houseware, and other packaging and consumer products.
The researchers believe that an industrial scale use of their method could eventually help reduce the volume of post-consumer waste in landfills by recycling plastics to desirable, highly valuable alkanes — but, of course, it's not that simple. The team says that more research into the effects of moisture and contaminants in the process is required, as well as product removal strategies to decrease the formation of light alkanes which will be critical for the industrialisation of this reaction.
However, they believe the path they're on could lead to affordable upcycling technology that would better integrate polyolefins into the global economy and incentivise the removal of waste plastics from landfill and the environment.
More about the study can be read here:
The Organisation for Economic Cooperation and Development (OECD) has published its Science Technology and Innovation Outlook 2021: Time of Crises and Opportunity report.
Published at the beginning of 2021, the report focuses on the ‘unparalleled mobilisation of the scientific and innovation community’ in response to the covid-19 pandemic. The report indicates that newly funded research initiatives have been established by public research agencies and organisations, private foundations and charities, while the health sector has similarly invested in an array of research programmes worth billions of dollars in record time.
The pandemic has led an unprecedented mobilisation of the scientific and innovation community
However, the report also exposes gaps in overall system resilience to future crises. ‘It’s a wake-up call that highlights the need to recalibrate science, technology and innovation (STI) policies, so that they better orient research and innovation efforts towards sustainability, inclusivity and resiliency goals,’ the report asserts.
Highlighting the rapid response by governments around the world, the report indicates that in the first few months of the pandemic, national research funding bodies spent around $5 billion on emergency financial support. This includes $300 million in Asia-Pacific, excluding China, over $850 million in Europe and more than $3.5 billion in North America. At the same time, research efforts led to around 75,000 scientific publications on covid-19 being released between January and November 2020, the report says. The largest share came from the US, followed by China and the UK. Research databases and scientific publishers removed paywalls so that covid-19 related information could be quickly shared.
Research efforts led to around 75,000 scientific publications on covid-19 being released between January and November 2020
‘These developments mark important changes that could accelerate the transition to a more open science in the longer run,’ the report says. It is also noted that not only have researchers continued their work with more than three quarters of scientists indicating that they had shifted to working from home at some point in 2020, but almost two thirds experienced, or expected to see, an increase in the use of digital tools for research as a consequence of the crisis. The report also mentions the contribution of the general public, with so called ‘frugal innovations’ in response to shortages of medical equipment and emergency supplies.
Looking to the future of the research community, the report says that postgraduate training regimes require reform to support a diversity of career paths. ‘The crisis has shown that the need for STI expertise is not limited to the public laboratory; it is also important for business, government and NGOs […] Reforming PhD and post-doctoral training to support a diversity of career paths is essential for improving societies’ ability to react to crises like covid-19 and to deal with long-term challenges like climate change that demand science-based responses […] There has been a 25% increase in the number of people with PhDs in OECD countries over the past decade with no corresponding increase in academic posts. The pandemic is expected to make matters worse, more than half of the scientists participating in the OECD Science Flash Survey expect the crisis to negatively affect their job security and career opportunities,’ the report says.
Post-graduate training regimes require reform to support a diversity of career paths
While still in the midst of the pandemic, the report stresses that STI policies now need to be reoriented to tackle the challenges of sustainability, inclusivity and resiliency. ‘In the short-term governments should continue their support for science and innovation activities that aim to develop solutions to the pandemic and mitigate its negative impacts, while paying attention to its uneven distributional effects. Science for policy will remain in the spotlight as governments seek to strike the right balance in their response to covid-19. This will effect public perceptions of science that could have long term implications for science-society relations.’
The report concludes that governments now have the task of developing public sector capabilities to deliver more ambitious STI policy. This will require engagement from stakeholders and citizens in order to capture a diversity of knowledge and values.